Published online before print April 21, 2008, doi: 10.1161/CIRCULATIONAHA.107.701243
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:2184-2191.)
© 2008 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome
From the Cardiology Division of the Department of Medicine (I.G., A.J.M., S.M., W.Z., M.L.A., J.L.R.), Biostatistics and Computational Biology (D.R.P.), and Pathology (M.Q.), University of Rochester Medical Center, Rochester, NY; Cardiovascular Department De Gasperis (E.H.L.), Niguarda Hospital, Milan, Italy; Departments of Medicine, Pediatrics, and Molecular Pharmacology (M.J.A.), Mayo Clinic College of Medicine, Rochester, Minn; Bikur Cholim Hospital (J.B.), University of Jerusalem, Jerusalem, Israel; Heart and Vascular Research Center (E.S.K.), MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio; Molecular Cardiology (C.N., S.G.P.), Fondazione S. Maugeri–University of Pavia, Pavia, Italy; Department of Cardiology (P.J.S.), Fondazione Policlinico S. Matteo IRCCS and University of Pavia, Pavia, Italy; Department of Pediatric Cardiology (J.A.T.), Baylor College of Medicine, Houston, Tex; and Department of Medicine (M.V., L.Z.), University of Utah School of Medicine, Salt Lake City.
Correspondence to Ilan Goldenberg, MD, Heart Research Follow-Up Program, Box 653, University of Rochester Medical Center, Rochester, NY 14642. E-mail Ilan.Goldenberg{at}heart.rochester.edu
Received March 6, 2007; accepted December 24, 2007.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— The congenital long-QT syndrome (LQTS) is an important cause of sudden cardiac death in children without structural heart disease. However, specific risk factors for life-threatening cardiac events in children with this genetic disorder have not been identified.
Methods and Results— Cox proportional-hazards regression modeling was used to identify risk factors for aborted cardiac arrest or sudden cardiac death in 3015 LQTS children from the International LQTS Registry who were followed up from 1 through 12 years of age. The cumulative probability of the combined end point was significantly higher in boys (5%) than in girls (1%; P<0.001). Risk factors for cardiac arrest or sudden cardiac death during childhood included corrected QT interval [QTc] duration >500 ms (hazard ratio [HR]; 2.72; 95% confidence interval [CI], 1.50 to 4.92; P=0.001) and prior syncope (recent syncope [<2 years]: HR, 6.16; 95% CI 3.41 to 11.15; P<0.001; remote syncope [
2 years]: HR, 2.67; 95% CI, 1.22 to 5.85; P=0.01) in boys, whereas prior syncope was the only significant risk factor among girls (recent syncope: HR, 27.82; 95% CI, 9.72 to 79.60; P<0.001; remote syncope: HR, 12.04; 95% CI, 3.79 to 38.26; P<0.001). β-Blocker therapy was associated with a significant 53% reduction in the risk of cardiac arrest or sudden cardiac death (P=0.01).
Conclusions— LQTS boys experience a significantly higher rate of fatal or near-fatal cardiac events than girls during childhood. A QTc duration >500 ms and a history of prior syncope identify risk in boys, whereas prior syncope is the only significant risk factor among girls. β-Blocker therapy is associated with a significant reduction in the risk of life-threatening cardiac events during childhood.
Key Words: death, sudden • long-QT syndrome • risk factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The congenital long-QT syndrome (LQTS) is caused by mutations that encode channels that regulate sodium, potassium, and calcium currents and by a mutation in a cytoskeletal gene (ankyrin B) that affects sodium and calcium kinetics, resulting in prolonged ventricular repolarization and an increased risk for sustained ventricular tachyarrhythmias.1 The genetic disorder is an important cause of sudden cardiac death (SCD) in children without structural heart disease.2 However, the risk in affected patients is not uniform because of variable penetrance and is influenced by age, gender, genotype, environmental factors, therapy, and possibly other modifier genes.3 In recent years, numerous advances have been made in the identification of the genotype-phenotype relationship and risk factors for cardiac events in LQTS patients.4–11 These data, however, were assessed mostly in studies that have included syncope as the predominant component in a composite cardiac event end point.
Editorial p 2178
Clinical Perspective p 2191
We have recently described the clinical course of LQTS patients during the adolescent12 and postadolescent13 periods and have shown that risk factors in this genetic disorder are age dependent. However, to date, specific risk factors for life-threatening cardiac events in LQTS children have not been assessed.
The objectives of the present study were to evaluate the contribution of prespecified genetic and clinical factors to the development of aborted cardiac arrest (ACA) or SCD in LQTS children, to determine whether interactions among risk factors can be used to identify risk subsets in this population, and to assess the efficacy of β-blocker therapy for the prevention of fatal or near-fatal cardiac events during childhood within the identified risk groups.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
The study population, drawn from the International LQTS Registry, involved children from proband-identified families.4 Children >1 year of age were considered to have LQTS if the QT interval corrected for heart rate ([QTc] assessed with Bazett’s formulas14) was
450 ms or if they had a documented LQTS mutation by genetic testing. Children were excluded from the analysis if they had a QTc <450 ms on the baseline ECG without a genotype positive mutation, experienced ACA or death or were lost to follow-up before 1 year of age, or were more than second-degree relatives of probands because of lack of complete information in the registry on the clinical course of more distant relatives of probands. The final study group comprised 3015 children from 1249 proband-identified families, of whom 875 subjects from 272 enrolled families underwent genetic testing and were identified as carriers of a known LQTS mutation. The LQTS genotype was determined with standard mutational analytic techniques involving 5 established genetic laboratories associated with the International LQTS Registry.
Data Collection and Management
Follow-up was closed on March 30, 2006. Those who had not reached their 13th birthday on that date were censored at the time of their last contact. Those who were lost to follow-up also were censored at the time of their last contact. Among the 3015 study patients, the mean±SD age at enrollment in the registry was 7.5±5.4 years. On enrollment, complete history was obtained from birth to their enrolled age, and ongoing clinical information was obtained at yearly intervals thereafter. In the present study, we assessed the clinical course of study patients from 1 through 12 years of age. Thus, follow-up time for each study patient comprised historical clinical information from 1 year of age to enrollment and prospective follow-up information from enrollment through 12 years of age if the patient had not otherwise been censored for any of the above reasons. For each patient, data on personal and family histories, cardiac events, and therapy were systematically recorded at enrollment and at each visit or medical contact. Clinical data, recorded on prospectively designed forms, included patient and family histories and demographic, ECG, therapeutic, and cardiac event information. Data on β-blocker therapy included the starting date, type of β-blocker, and discontinuation date if appropriate. After a fatal event, the use of a β-blocker before death was determined retrospectively. Among the 3015 study patients, 2 died of non-LQTS causes, 32 were lost to follow-up and censored at the time of their last contact, and 329 had not reached their 13th birthday when follow-up was closed.
All patients or their guardians provided informed consent agreeing to inclusion in the registry and subsequent clinical studies. The study was approved by the University of Rochester Medical Center Institutional Review Board.
End Point
The primary end point of the study was time to ACA (requiring external defibrillation as part of the resuscitation) or LQTS-related SCD (death abrupt in onset without evident cause if witnessed or death that was not explained by any other cause if it occurred in a nonwitnessed setting such as sleep), whichever occurred first, from 1 through 12 years of age.
Statistical Analysis
The clinical characteristics of study patients were compared by gender through the use of the 
2 test for categorical variables, and the t test (and the Mann-Whitney-Wilcoxon test used for comparison between drug dosages) was used for continuous variables. The Kaplan–Meier estimator was used to assess the time to a first life-threatening event and the cumulative event rates by risk factors and risk groups, and groups were compared through the use of the log-rank test.
Multivariable Cox proportional-hazards regression analysis was carried out in the total study population and separately in the subset of study patients who were genetically tested and identified as carriers of a known LQTS mutation. Prespecified candidate risk factors in the total population model included male gender, syncope (defined as transient loss of consciousness that was abrupt in onset and offset), family history of SCD in a first-degree relative, QTc duration >500 ms on the baseline ECG, and congenital deafness. The occurrence of SCD in a family member and the occurrence of syncope in an affected individual were evaluated in a time-dependent manner. To evaluate the independent contribution of the timing of non–life-threatening cardiac events to the development of ACA or SCD, syncopal history was modeled as a 3-level time-dependent categorical predictor X(t): Xi(t)="recent" if subject i had 1+ events during the time interval (t–2 years, t); Xi(t)="remote" if subject i had 1+ events during (–1 year, t–2 years) but no events during (t–2 years, t); and Xi(t)="none" if subject i had no events between birth (t=–1 year owing to the time origin of age 1 year) and time t. Interactions between predictors found to be significantly associated with the outcome were further evaluated in the multivariable Cox models. Interactions between risk factors were considered if thought to be clinically plausible and were included in the model if the ratio of the hazard ratios (HRs) for the risk factors across patient subsets was >2.5 with P<0.1. Because therapy with β-blockers was given at the discretion of each subject’s attending physician to those considered to be at high risk, the efficacy of time-dependent β-blocker therapy in reducing the risk of the end point also was related to the presence of risk factors via prespecified β-blocker–by–risk factor interaction terms.
In the model that included only genetically tested individuals, findings also were adjusted for the presence of the 3 main LQTS genotypes (LQT1, LQT3, and LQT3) and other genotypes (LQT5 through LQT8 [n=11], which were included as a single covariate). Patients who had multiple mutations in different genes (n=14) were not included in the genotyped model. Because patients who underwent genetic testing did not have a QTc threshold for exclusion from the study, we carried out an additional exploratory analysis in this population in which QTc was further categorized into subgroups of <450, 450 to 500, and >500 ms to assess the rate of life-threatening cardiac events in LQTS children with low to normal QTc durations.
All models were stratified by the decade in which study patients were born to account for changes in the baseline hazard function for different calendar time periods. No adjustments for potential dependencies resulting from family membership were required because no more than 1 ACA/SCD was observed from 1 to 12 years of age in any given family.15
The statistical software used for the analyses was SAS version 9.13 (SAS Institute Inc, Cary, NC). A 2-sided significance level of 0.05 was used for hypothesis testing, whereas the 2-tailed level of 0.10 was used for including predictors in the Cox models.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
The clinical characteristics of study patients by gender are shown in Table 1. Girls made up 63% of the patients and had a significantly longer QTc duration compared with boys, whereas other ECG parameters were similar in boys and girls.
|
Male patients exhibited a significantly higher proportion of all types of LQTS-related cardiac events during follow-up compared with female patients and accordingly received a higher proportion of medical and nonmedical therapies for the genetic disorder (Table 2).
|
Genotyped patients had a gender distribution (Table 1) and a mean QTc duration (490±54 ms) that were similar to those of the total population. However, patients who underwent genetic testing displayed several important clinical differences compared with nongenotyped individuals, including a lower frequency of probands (31% versus 45%, respectively; P<0.001), a higher frequency of SCD in affected family members (9% versus 4%, respectively; P<0.001), and a higher frequency of therapy with β-blockers during follow-up (22% versus 18%, respectively; P=0.006). Accordingly, the subset of study patients who were genotyped experienced a relatively low rate of LQTS-related life-threatening cardiac events during childhood (ACA, 1.2%; SCD, 0.5%).
Risk Factors for Life-Threatening Cardiac Events in LQTS Children
Total Population
Male gender, time-dependent syncope, and a QTc duration >500 ms were identified as significant predictors of life-threatening cardiac events during childhood among study patients. Furthermore, the effect of each of these 3 clinical factors displayed important differences among risk subsets of LQTS children (Tables 3 and 4
; the corresponding number of patients, follow-up time, and crude event rates for each risk subset are provided in the Appendix of the online-only Data Supplement). By contrast, a family history of SCD in a first-degree relative was not shown to be a significant predictor of outcome during childhood (HR, 0.82; 95% confidence interval [CI], 0.26 to 2.60; P=0.73). Patients born with congenital deafness had a >3-fold increase in the risk of life-threatening cardiac events during childhood without adjustment for a history of prior syncope (unadjusted HR, 3.22; 95% CI, 1.38 to 7.49; P=0.007). However, when time-dependent syncope was added to the multivariable model, the risk associated with congenital deafness was no longer evident (adjusted HR, 0.89; 95% CI, 0.38 to 2.15; P=0.80). Of note, virtually identical results on risk factors were obtained after patients who were born with congenital deafness were removed from the analysis.
|
|
Male patients experienced a significantly higher rate of life-threatening cardiac events during childhood (5%) than female patients (1%; Figure 1). The relative risk of boys versus girls was most pronounced in asymptomatic (eg, without prior syncope) LQTS children who had a prolonged QTc duration and was attenuated after an LQTS child became symptomatic (eg, experienced syncope) during follow-up (Table 3).
|
A QTc duration >500 ms was associated with a nearly 3-fold increase in the risk of fatal or near-fatal events in LQTS boys, whereas QTc duration was not a significant risk factor among girls (Table 4). Accordingly, the cumulative rate of ACA or SCD during childhood was significantly higher among boys with a QTc duration >500 ms than among boys with a shorter QTc duration or girls regardless of their QTc duration (Figure 2).
|
Time-dependent syncope was shown to be the most powerful predictor of outcome in both LQTS boys and girls (Table 4). Notably, the risk associated with a history of syncope was significantly higher in girls than in boys (P=0.01 for gender-by–prior syncope interaction) and most pronounced when the event occurred within the past 2 years. However, even more remote syncope was associated with a significant and substantial increase in the risk of subsequent life-threatening events during childhood in both boys and girls (Table 4).
The nature of time-dependent covariates precludes assessment of cumulative event rates based only on the covariate pattern at the time origin. Therefore, to obtain an estimate of event rates during childhood for patients who experienced syncope during follow-up, we identified time-independent risk groups at 6 years of age, stratified by the occurrence of syncope before 6 years of age, and evaluated the cumulative probability of ACA or SCD from 6 through 12 years of age (Figure 3). This analysis demonstrated that the rate of life-threatening events during childhood was highest among boys who experienced prior syncope (15%), intermediate in girls with a history of syncope and asymptomatic boys (4% and 3%, respectively), and lowest in girls without a history of prior syncope (0.6%; P<0.001).
|
Genotyped Patients
When predictors of life-threatening cardiac events were analyzed in the subgroup of LQTS children who were genotyped, clinical factors, including time-dependent syncope (HR, 4.23; 95% CI, 1.13 to 15.85; P=0.03) and male gender (HR, 5.05; 95% CI, 1.08 to 23.53; P=0.04), were identified as predictors of outcome, whereas nonsignificant differences in the risk for life-threatening cardiac events were shown among the 3 major LQTS genotypes (LQT1 versus LQT2: HR, 1.83; 95% CI, 0.36 to 9.17; P=0.46; LQT3 versus LQT2: HR, 2.95; 95% CI, 0.26 to 33.16; P=0.38; LQT3 versus LQT1: HR, 1.62; 95% CI, 0.18 to 14.47; P=0.67). Interactions among clinical factors and between clinical factors and genotypes were not significant in the model that included the genotyped population, possibly because of the relatively low event rate in this subset of study patients.
A QTc duration >500 ms was associated with a statistically nonsignificant >2-fold increase in the risk of ACA or SCD in the genotyped population (HR, 2.68; 95% CI, 0.69 to 10.49; P=0.16). Notably, no life-threatening cardiac events occurred in genotyped patients who exhibited low to normal QTc durations (<450 ms [n=127]), whereas the cumulative probability of ACA or SCD in patients with intermediate (450 to 500 ms [n=437]) and high (>500 ms [n=239]) QTc durations was 1% and 3%, respectively (P=0.037 for the comparison among the 3 QTc subgroups).
β-Blocker Efficacy During Childhood
β-Blocker therapy was initiated at some point during childhood for 643 study patients (21%), of whom 67 (10%) discontinued the medication before termination of follow-up. The main β-blocker subtypes and their respective mean dosages are shown in Table 2.
Patients who were treated with β-blockers during childhood had a higher frequency of risk factors compared with untreated LQTS children (QTc duration: 501±50 versus 489±48 ms, respectively [P<0.001]; prior syncope: 52% versus 12%, respectively [P<0.001]; male gender: 56% versus 33%, respectively [P<0.001]).
In multivariable analysis, β-blocker therapy was independently associated with a significant 53% reduction in the risk of ACA or SCD during childhood (HR, 0.47; 95% CI, 0.26 to 0.85; P=0.01). The benefit of β-blocker therapy was pronounced among high-risk children who experienced syncope during the past 2 years (HR, 0.27; 95% CI, 0.12 to 0.62; P=0.002) and significantly attenuated (HR, 0.95; 95% CI, 0.41 to 2.21; P=0.90) in lower-risk children with more remote or no syncope (for β-blocker–by–recent syncope interaction, P=0.03). However, despite the significant beneficial effects of β-blockers, the rate of life-threatening cardiac events among high-risk children who were treated with β-blockers was considerable: Boys on β-blockers as of 6 years of age who experienced syncope before 6 years of age had a 12% cumulative probability of ACA or SCD during the subsequent 7 years of follow-up, corresponding to an average annual event rate of nearly 2% while on medical therapy.
Other LQTS-Related Therapies During Childhood
Additional therapeutic modalities were used infrequently during childhood and are considered separately below. Medical therapy with mexiletine and flecainide was administered to a small number of study patients (Table 2). Twenty-nine study patients received mexiletine, of whom 2 (7%) had ACA or SCD during treatment. Flecainide was administered to only 5 patients (mostly LQT3 genotype carriers or their family members), of whom 1 experienced SCD during therapy.
Forty-one study patients (1%) received an implantable cardioverter-defibrillator (ICD) during childhood. The device was implanted at a mean±SD age of 7.3±0.5 years. Twelve patients experienced ACA before implantation, and 29 experienced at least 1 episode of syncope before implantation (mean±SD, 2.5±0.4 episodes). The combined end point of ACA or SCD occurred in 1 patient who was affected with Timothy syndrome (ICD implanted at 2.5 years of age as a result of recurrent syncope despite β-blocker therapy; age at death, 5.1 years; mode of death, electrical storm [persistent torsade de pointes despite 25 ICD shocks]) during a mean±SD follow-up period of 2.7±0.3 years. Interrogation data were available for a subset of 20 LQTS children (49%) with an ICD, of whom 8 (40%) experienced at least 1 appropriate ICD discharge during the same follow-up period.
Left cervical sympathetic denervation was carried out in 40 patients (1%) during childhood. The procedure was performed at a mean±SD age of 7.4±0.4 years. Similar to patients treated with an ICD, children who underwent left cervical sympathetic denervation experienced prior syncope (n=27) or prior ACA (n=13). None of the patients who underwent left cervical sympathetic denervation experienced a life-threatening cardiac event after the procedure during a mean±SD follow-up period of 3.9±0.4 years.
A cardiac pacemaker was implanted in 70 children at a mean±SD age of 6.2±0.4 years, 9 of whom had ACA before implantation. The combined end point of ACA or SCD occurred in 6 patients after implantation of a pacemaker during a mean±SD follow-up period of 4.0±0.5 years.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Three main implications emerge from the present study about the risk of life-threatening cardiac events in LQTS children: (1) risk factors for ACA or SCD can be assessed from clinical history and examination of the ECG and include male gender, a history of syncope at any time during childhood, and a QTc duration >500 ms; (2) significant interactions exist among the 3 clinical risk factors that can identify risk subsets in this population; and (3) β-blocker therapy is associated with a significant reduction in the risk of life-threatening cardiac events in LQTS children. However, the rate of ACA or SCD in high-risk children who experience syncope is still considerable despite β-blocker therapy.
The present study is the first to focus solely on the end point of life-threatening cardiac events in young, preadolescent LQTS children. We have shown that the rate of fatal or near-fatal events in children with this genetic disorder is significantly higher among boys than among girls throughout childhood, resulting in a significantly higher cumulative event rate in preadolescent boys despite the fact that girls exhibited a significantly longer mean QTc duration and had similar baseline heart rates. Notably, asymptomatic boys with a prolonged QTc duration exhibited a >12-fold increase in the risk of life-threatening cardiac events compared with the respective girls, whereas after the occurrence of syncope during follow-up, the relative risk associated with male gender was attenuated.
Our findings are consistent with previous data on gender differences in the risk of LQTS-related cardiac events.8,9 Two recent studies from the International LQTS Registry that have focused on LQTS adolescents12 and adults13 demonstrated that the gender-related risk reverses after childhood, and female patients maintain higher risk than male patients throughout adolescence and during adulthood. The mechanisms behind these age-dependent differences in gender-related risk are unknown. The predominance of life-threatening cardiac events among boys during the first decade of life may be related to environmental factors or to the presence of modifier genes, whereas the opposing effects of estrogen and androgens on ventricular repolarization (increase and decrease in QTc duration, respectively) have been suggested as a possible mechanism for the male versus female risk reversal with the onset of adolescence.16–19 Ventricular tachyarrhythmias have been shown to occur more frequently during physical effort in patients carrying the common LQT1 genotype,11 possibly because of a lack of adaptive QT shortening with decreasing RR intervals during tachycardia.20 Boys may participate more frequently in intensive physical activity than girls during childhood as a result of environmental influences, and this factor may contribute to the gender-related risk of life-threatening tachyarrhythmias in this age group. It also is possible that modifier genes exist that are not shared by boys and girls (eg, on the Y chromosome), which contribute to the higher risk of LQTS boys early in life. Thus, interactions among environmental, genetic, and hormonal factors need to be further evaluated in this genetic disorder. At present, our data suggest that LQTS boys should be followed up carefully for both QTc duration and the development of clinical symptoms and should be offered primary therapies for this genetic disorder during childhood on the basis of either of these 2 risk factors, whereas LQTS girls who do not experience syncope appear to maintain a relatively low risk for ACA or SCD during childhood regardless of their QTc duration.
Genotype data have been shown to be useful for risk stratification in LQTS patients when syncope is a component of the cardiac end point.6,7 However, in the present study, a history of syncope was used as a time-dependent covariate in the multivariable model that assessed the end point of ACA or SCD. Using this methodology, we have shown that among genotyped study patients, data on a specific genotype (LQT1, LQT2, or LQT3) did not contribute significantly to outcome, whereas clinical risk factors, including male gender and time-dependent syncope, maintained their significance as powerful predictors of outcome. Nevertheless, only 2% of genotyped patients experienced a fatal or near-fatal event during childhood. Thus, it is possible that the study may be underpowered to detect statistically significant differences in the risk conferred by the 3 main LQTS genotypes or interactions between clinical factors and genotypes. Similarly, despite the fact that children born with congenital deafness experienced a significantly higher frequency of life-threatening cardiac events (10%) compared with those without congenital deafness (2%), this factor did not make a significant contribution to outcome after multivariable adjustment, possibly because all patients with congenital deafness who had a life-threatening cardiac event during childhood also experienced syncope before the event, making the latter symptom the predominant risk factor in the multivariable model.
β-Blocker therapy was associated with a significant reduction in the risk of life-threatening cardiac events in the study population, with a more pronounced effect in high-risk patients who experienced recent syncope, suggesting that this mode of medical therapy should be considered a first-line measure in LQTS children. The lack of a significant effect of β-blocker therapy in lower-risk patients does not imply that this mode of medical therapy should not be prescribed to symptomatic boys or girls with remote syncope or boys with a prolonged QTc interval duration. β-Blockers were administered to those considered to be at risk by the treating physician, and unmeasured risk factors may have been more unbalanced in patients with lower-risk features. Nevertheless, despite the highly significant beneficial effects of β-blockers in high-risk children and the possible beneficial effects in lower-risk subsets, children with a history of syncope who were treated with β-blockers still displayed a substantial burden of life-threatening events while on medical therapy. Other therapeutic modalities, including implantation of an ICD and left cervical sympathetic denervation, have been shown to be effective in LQTS patients.21,22 These more invasive medical procedures should be considered for the primary prevention of life-threatening cardiac events in LQTS children in whom symptoms persist despite β-blocker therapy.
Study Limitations
Despite the relatively large sample size of the present study, only 53 first life-threatening cardiac events were recorded in boys and, more importantly, only 20 among girls. This relatively low event rate, especially among girls, could have contributed to the unexpectedly large 12- to 28-fold HR estimates for remote and recent syncope among girls and the 4.5-fold interaction of gender with syncope. Therefore, although these effects were statistically significant at the 0.01 level, future analyses of the expanding LQTS Registry may be needed to validate and better estimate the identified interactions with gender, the relative risks among girls, and the effect of genetic factors on outcome during childhood.
Conclusions and Clinical Implications
The present study of LQTS children and a recent report from the International LQTS Registry on the clinical course of LQTS adolescents12 consistently demonstrate that risk factors for life-threatening cardiac events can be assessed from clinical history and the surface ECG. Importantly, the results of the 2 studies suggest that careful follow-up is warranted in LQTS patients because risk factors for life-threatening cardiac events are time dependent and age specific, resulting in a substantial variability in the phenotypic expression of this genetic disorder during long-term follow-up.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by research grants HL-33843 and HL-51618 from the National Institutes of Health, Bethesda, Md, and by a research grant to the University of Rochester from Genaissance Pharmaceuticals.
Disclosures
The University of Rochester (Dr Moss) received a grant from Genaissance Pharmaceuticals that supported research for the detection of LQTS-related ion channel mutations. Dr Ackerman reports that he is a consultant for Clinical Data (formerly Genaissance Pharmaceuticals) with respect to the FAMILION genetic test for cardiac ion channel mutations and holds significant interest in intellectual property related to ion channel patents. The other authors report no conflicts.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000; 102: 1178–1185.
2. Vincent GM. The long QT and Brugada syndromes: causes of unexpected syncope and sudden cardiac death in children and young adults. Semin Pediatr Neurol. 2005; 1: 15–24.
3. Moss AJ. Long QT syndrome. JAMA. 2003; 289: 2041–2044.
4. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991; 84: 1136–1144.
5. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004; 292: 1341–1344.
6. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of genotype on the clinical course of the long-QT syndrome: International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998; 339: 960–965.
7. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med. 2003; 348: 1866–1874.
8. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998; 97: 2237–2244.
9. Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, Schwartz PJ, Vincent GM, Priori SG, Benhorin J, Towbin JA, Robinson JL, Andrews ML, Napolitano C, Timothy K, Zhang L, Medina A, for the International Long QT Syndrome Registry. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol. 2003; 42: 103–109.
10. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992; 327: 846–852.[Abstract]
11. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001; 103: 89–95.
12. Hobbs JB, Peterson DR, Moss AJ, McNitt S, Zareba W, Goldenberg I, Qi M, Robinson JL, Sauer AJ, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Towbin JA, Vincent GM, Zhang L. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006; 296: 1249–1254.
13. Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson JL, Qi M, Goldenberg I, Hobbs JB, Ackerman MJ, Benhorin J, Hall WJ, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L. Long QT syndrome in adults. J Am Coll Cardiol. 2007; 49: 329–337.
14. Bazett HC. An analysis of the time relations of electrocardiograms. Heart. 1920; 7: 353–367.
15. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY; Springer-Verlag; 2000.
16. Bidoggia H, Maciel JP, Capalozza N, Mosca S, Blaksley EJ, Valverde E, Bertran G, Arini P, Biagetti MO, Quinteiro RA. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone. Am Heart J. 2000; 140: 678–683.[CrossRef][Medline] [Order article via Infotrieve]
17. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 1996; 94: 1471–1474.
18. Liu XK, Katchman A, Drici MD, Ebert SN, Ducic I, Morad M, Woosley RL. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther. 1998; 285: 672–679.
19. Boyle MB, MacLusky NJ, Naftolin F, Kaczmarek LK. Hormonal regulation of K+-channel messenger RNA in rat myometrium during oestrus cycle and in pregnancy. Nature. 1987; 330: 373–375.[CrossRef][Medline] [Order article via Infotrieve]
20. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol. 1999; 34: 823–829.
21. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003; 14: 337–341.[CrossRef][Medline] [Order article via Infotrieve]
22. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004; 109: 1826–1833.
|
Footnotes |
|---|
The online-only Data Supplement, which contains tables, can be found with this article at http://circ.ahajournals.org/cgi/content/full/ CIRCULATIONAHA.107.701243/DC1.
This article has been cited by other articles:
 |
|
 |
|
  R. RAMARAJ Long QT syndrome: (AUGUST 2008) Cleveland Clinic Journal of Medicine, February 1, 2009; 76(2): 87 - 87. [Full Text] [PDF]
|
|
|
|
|
|
E. LEVINE and J. P. DAUBERT IN REPLY: Cleveland Clinic Journal of Medicine, February 1, 2009; 76(2): 88 - 88. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Goldenberg and A. J. Moss Long QT syndrome. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2291 - 2300. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||